WLWenyuan Li

Wenyuan Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenyuan Li has a total of 148 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Methylation plus alpha-fetoprotein blood test for early detection of HCC in at-risk populations

    by Neehar D. Parikh, Chun-Chi Liu, Matthew DeMaio, Angela H. Yeh, Mary L. Stackpole, Shuo Li, Vatche G. Agopian, Wenyuan Li, Xianghong Jasmine Zhou, Xiaohui Ni, et al.

    Background: Semi-annual abdominal ultrasound plus alpha-fetoprotein (AFP) is recommended for HCC surveillance but has limited performance, particularly in patients with metabolic dysfunction–associated steatotic liver disease. We aimed to validate a blood-based test combining cell-free DNA methylation profiling with AFP to improve HCC detection in at-risk individuals. Methods: Between September 1, 2023, and April 30, 2025, 135 patients with HCC and 167 at risk for HCC were prospectively recruited at 2o medical centers; archived samples (46 HCC and 32 at-risk) were also included. A cell-free DNA methylation assay was performed to generate methylation scores, and AFP testing was conducted as part of standard of care. A pretrained model integrated methylation scores and AFP levels for HCC detection. Results: The combination of methylation and AFP tests achieved an AUC of 0.94 (95% CI, 0.92–0.96) for detecting HCC in at-risk individuals, significantly outperforming both methylation alone (AUC: 0.92, 95% CI, 0.89–0.95; p =0.001) and AFP alone (AUC: 0.83, 95% CI, 0.79–0.87; p p =0.002) and AFP alone (AUC: 0.81, 95% CI, 0.76–0.86; p p =0.025) for methylation alone and 52% (95% CI, 43%–62%; p <0.0001) for AFP alone. Sensitivity improvements were consistent across major demographic and etiologic subgroups. Conclusions: The combination of cell-free DNA methylation with AFP shows promising performance for early-stage HCC detection in this case-control validation study and warrants further validation.

  • Open Access

    Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test

    by Weihua Zeng, Chun-Chi Liu, Shuo Li, Yonggang Zhou, Mary L. Stackpole, Ying Xiao, Ran Hu, Caitlin Tang, Qiao Liu, Wanwen Zeng, et al.

    Plasma cell-free DNA (cfDNA), originating from multiple organs, holds significant potential for noninvasive diagnostics and prognostics. Current cfDNA methylation assays primarily focus on single clinical indications by targeting specific genomic loci. In contrast, comprehensive profiling of cfDNA methylome can enable simultaneous detection of multiple diseases by capturing organ-specific methylation signatures, thereby offering a holistic view of health, when disease etiology is unclear or when conventional biochemical diagnostics are unavailable. However, deep sequencing required for sensitive detection of methylation abnormalities remains prohibitively expensive, limiting widespread clinical use. To overcome this barrier, we developed MethylScan , a highly cost-effective approach for cfDNA methylome sequencing. We demonstrated its broad clinical utility in a cohort of 1,061 individuals across diverse applications, including multicancer detection in general population, liver cancer surveillance in high-risk individuals, liver disease classification, identification of organ abnormalities, and race prediction from cfDNA. In multicancer detection (liver, lung, ovarian, and stomach cancers), MethylScan achieved an area under the receiver operating characteristic curve (AUROC) of 0.938 (95% CI: 0.920 to 0.954), with a sensitivity of 63.3% (95% CI: 58.9 to 67.9%) at 98.0% specificity for all cancer stages. For early-stage cancers, the AUROC was 0.916 (95% CI: 0.890 to 0.940), with 55.3% sensitivity (95% CI: 49.1 to 62.1%) at the same specificity. In liver cancer surveillance, MethylScan achieved an AUROC of 0.927 (95% CI: 0.889 to 0.959), with 79.6% sensitivity (95% CI: 70.6 to 87.8%) at 90.4% specificity. The assay also demonstrated strong performance in additional diagnostic tasks, supporting its potential as a versatile platform for comprehensive cfDNA-based health monitoring.


  • Open Access

    Reducing demographic bias in biomedical machine learning for cancer detection using cfDNA methylation

    by Shuo Li, Weihua Zeng, Wenyuan Li, Chun-Chi Liu, Yonggang Zhou, Xiaohui Ni, Mary L. Stackpole, Angela H. Yeh, Andrew Melehy, David S. Lu, et al.

    Background: Machine learning models in biomedical research are often hindered by demographic imbalances in clinical datasets, leading to biased predictions that disadvantage minority populations. Existing bias-correction methods face limitations in handling the heterogeneity of biomedical data and the complexity of demographic influences. Results: We present DeBias , a computational framework for mitigating demographic biases in high-dimensional biomedical datasets. DeBias identifies and removes bias-associated subspaces from the feature space using control samples, enabling global correction of demographic distortions while preserving disease-specific signals. To evaluate its effectiveness, we apply DeBias to cell-free DNA methylation data for cancer detection. DeBias achieves a significant reduction in the number of features exhibiting demographic bias and outperforms existing methods in improving cancer detection performance for minority populations. Performance gains are validated in independent cohorts, highlighting the robustness of the approach. Conclusions: DeBias offers an effective and generalizable strategy for correcting demographic biases in biomedical machine learning. It represents a step toward more equitable machine learning models that can deliver reliable and unbiased predictions across diverse patient populations.


  • Open Access

    Author Correction: Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis

    by Shuo Li, Zorawar S. Noor, Weihua Zeng, Mary L. Stackpole, Xiaohui Ni, Yonggang Zhou, Zuyang Yuan, Wing Hung Wong, Vatche G. Agopian, Steven M. Dubinett, et al.

  • Open Access

    Noninvasive prognostication of hepatocellular carcinoma based on cell-free DNA methylation

    by Ran Hu, Benjamin Tran, Shuo Li, Mary L. Stackpole, Weihua Zeng, Yonggang Zhou, Andrew Melehy, Saeed Sadeghi, Richard S. Finn, Xianghong Jasmine Zhou, et al.

    Background: The current noninvasive prognostic evaluation methods for hepatocellular carcinoma (HCC), which are largely reliant on radiographic imaging features and serum biomarkers such as alpha-fetoprotein (AFP), have limited effectiveness in discriminating patient outcomes. Identification of new prognostic biomarkers is a critical unmet need to improve treatment decision-making. Epigenetic changes in cell-free DNA (cfDNA) have shown promise in early cancer diagnosis and prognosis. Thus, we aim to evaluate the potential of cfDNA methylation as a noninvasive predictor for prognostication in patients with active, radiographically viable HCC. Methods: Using Illumina HumanMethylation450 array data of 377 HCC tumors and 50 adjacent normal tissues obtained from The Cancer Genome Atlas (TCGA), we identified 158 HCC-related DNA methylation markers associated with overall survival (OS). This signature was further validated in 29 HCC tumor tissue samples. Subsequently, we applied the signature to an independent cohort of 52 patients with plasma cfDNA samples by calculating the cfDNA methylation-based risk score (methRisk) via random survival forest models with 10-fold cross-validation for the prognostication of OS. Results: The cfDNA-based methRisk showed strong discriminatory power when evaluated as a single predictor for OS (3-year AUC = 0.81, 95% CI: 0.68–0.94). Integrating the methRisk with existing risk indices like Barcelona clinic liver cancer (BCLC) staging significantly improved the noninvasive prognostic assessments for OS (3-year AUC = 0.91, 95% CI: 0.80–1), and methRisk remained an independent predictor of survival in the multivariate Cox model (P = 0.007). Conclusions: Our study serves as a pilot study demonstrating that cfDNA methylation biomarkers assessed from a peripheral blood draw can stratify HCC patients into clinically meaningful risk groups. These findings indicate that cfDNA methylation is a promising noninvasive prognostic biomarker for HCC, providing a proof-of-concept for its potential clinical utility and laying the groundwork for broader applications.


  • Open Access

    cfTools: an R/Bioconductor package for deconvolving cell-free DNA via methylation analysis

    by Ran Hu, Shuo Li, Mary L Stackpole, Qingjiao Li, Xianghong Jasmine Zhou, Wenyuan Li

    Motivation: Cell-free DNA (cfDNA) released by dying cells from damaged or diseased tissues can lead to elevated tissue-specific DNA, which is traceable and quantifiable through unique DNA methylation patterns. Therefore, tracing cfDNA origins by analyzing its methylation profiles holds great potential for detecting and monitoring a range of diseases, including cancers. However, deconvolving tissue-specific cfDNA remains challenging for broader applications and research due to the scarcity of specialized, user-friendly bioinformatics tools. Results: To address this, we developed cfTools, an R package that streamlines cfDNA tissue-of-origin analysis for disease detection and monitoring. Integrating advanced cfDNA tissue deconvolution algorithms with R/Bioconductor compatibility, cfTools offers data preparation and analysis functions with flexible parameters for user-friendliness. By identifying abnormal cfDNA compositions, cfTools can infer the presence of underlying pathological conditions, including but not limited to cancer. It simplifies bioinformatics tasks and enables users without advanced expertise to easily derive biologically interpretable insights from standard preprocessed sequencing data, thus increasing its accessibility and broadening its application in cfDNA-based disease studies. Availability and implementation: cfTools and its supplementary package cfToolsData are freely available at Bioconductor: https://bioconductor.org/packages/release/bioc/html/cfTools.html and https://bioconductor.org/packages/release/data/experiment/html/cfToolsData.html. The development version of cfTools is maintained on GitHub: https://github.com/jasminezhoulab/cfTools.


  • Open Access

    Author Correction: Cost-effective methylome sequencing of cell-free DNA for accurately detecting and locating cancer

    by Mary L. Stackpole, Weihua Zeng, Shuo Li, Chun-Chi Liu, Yonggang Zhou, Shanshan He, Angela Yeh, Ziye Wang, Fengzhu Sun, Qingjiao Li, et al.


  • Open Access

    Author Correction: cfSNV: a software tool for the sensitive detection of somatic mutations from cell-free DNA

    by Shuo Li, Ran Hu, Colin Small, Ting-Yu Kang, Chun-Chi Liu, Xianghong Jasmine Zhou, Wenyuan Li

  • Open Access

    Evaluating the role of the nuclear microenvironment in gene function by population-based modeling

    by Asli Yildirim, Nan Hua, Lorenzo Boninsegna, Yuxiang Zhan, Guido Polles, Ke Gong, Shengli Hao, Wenyuan Li, Xianghong Jasmine Zhou, Frank Alber

    The nuclear folding of chromosomes relative to nuclear bodies is an integral part of gene function. Here, we demonstrate that population-based modeling—from ensemble Hi-C data—provides a detailed description of the nuclear microenvironment of genes and its role in gene function. We define the microenvironment by the subnuclear positions of genomic regions with respect to nuclear bodies, local chromatin compaction, and preferences in chromatin compartmentalization. These structural descriptors are determined in single-cell models, thereby revealing the structural variability between cells. We demonstrate that the microenvironment of a genomic region is linked to its functional potential in gene transcription, replication, and chromatin compartmentalization. Some chromatin regions feature a strong preference for a single microenvironment, due to association with specific nuclear bodies in most cells. Other chromatin shows high structural variability, which is a strong indicator of functional heterogeneity. Moreover, we identify specialized nuclear microenvironments, which distinguish chromatin in different functional states and reveal a key role of nuclear speckles in chromosome organization. We demonstrate that our method produces highly predictive three-dimensional genome structures, which accurately reproduce data from a variety of orthogonal experiments, thus considerably expanding the range of Hi-C data analysis.


  • Open Access

    Comprehensive tissue deconvolution of cell-free DNA by deep learning for disease diagnosis and monitoring

    by Shuo Li, Weihua Zeng, Xiaohui Ni, Qiao Liu, Wenyuan Li, Mary L. Stackpole, Yonggang Zhou, Arjan Gower, Kostyantyn Krysan, Preeti Ahuja, et al.

    Plasma cell-free DNA (cfDNA) is a noninvasive biomarker for cell death of all organs. Deciphering the tissue origin of cfDNA can reveal abnormal cell death because of diseases, which has great clinical potential in disease detection and monitoring. Despite the great promise, the sensitive and accurate quantification of tissue-derived cfDNA remains challenging to existing methods due to the limited characterization of tissue methylation and the reliance on unsupervised methods. To fully exploit the clinical potential of tissue-derived cfDNA, here we present one of the largest comprehensive and high-resolution methylation atlas based on 521 noncancer tissue samples spanning 29 major types of human tissues. We systematically identified fragment-level tissue-specific methylation patterns and extensively validated them in orthogonal datasets. Based on the rich tissue methylation atlas, we develop the first supervised tissue deconvolution approach, a deep-learning-powered model, cfSort , for sensitive and accurate tissue deconvolution in cfDNA. On the benchmarking data, cfSort showed superior sensitivity and accuracy compared to the existing methods. We further demonstrated the clinical utilities of cfSort with two potential applications: aiding disease diagnosis and monitoring treatment side effects. The tissue-derived cfDNA fraction estimated from cfSort reflected the clinical outcomes of the patients. In summary, the tissue methylation atlas and cfSort enhanced the performance of tissue deconvolution in cfDNA, thus facilitating cfDNA-based disease detection and longitudinal treatment monitoring.